投资者关系活动类别 ☐特定对象调研 ☐分析师会议 ☐媒体采访 业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 ☐其他 参与单位名称及人员 姓名 线上参与公司2024年度业绩说明会的全体投资者 时间 2025年4月18日 15:30-16:30 地点 价值在线（www.ir-online.cn） 上市公司接待人员姓名 董事长兼总经理 苏本立先生 独立董事 王立新女士 财务总监 冯正春先生 董事会秘书 华舜阳先生 投资者关系活动主要 内容介绍 一、投资者问答交流环节 公司与投资者在本次业绩说明会进行了沟通交流，主 要问题及回复如下： 1.领导好，去年营收增长的主要因素是什么？ 答：尊敬的投资者您好，2024年度，公司实现营业收 入101,747.40万元，同比增长24.65%，归属于上市公司股 东的净利润8,465.17万元，同比增长62.93%，加权平均净 1 证券代码：301011 证券简称：华立科技 广州华立科技股份有限公司 投资者关系活动记录表 编号：2025-002 答：投资者您好，公司将以"IP生态化运营"为核心， 加强研发投入与市场拓展，深化业务创新与资源整合，加 快产品迭代升级，以推动公司业务实 ...

Group 1: Product Development and Innovation - In 2024, the company advanced multiple R&D projects, including the development of non-backing enamel boards and key preparation technologies for ferritic stainless steel enamel boards, resulting in 12 new patents [1] - The company achieved recognition for its innovations, with the "Key Preparation Technology for Super Large Multi-functional Enamel Boards" awarded as a 2024 Zhejiang Province Advanced (Future) Technology Innovation Achievement [1] Group 2: Financial Performance and Profit Distribution - The profit distribution plan for 2024 proposes a cash dividend of RMB 0.14 per 10 shares based on a total share capital of 503,171,090 shares as of December 31, 2024 [2] - The company has maintained a cumulative cash dividend amount exceeding 100% of the average annual net profit over the past three years [3] Group 3: Market Position and Competitive Advantage - The company is a leading player in the new functional enamel materials sector, with strong R&D capabilities and a high level of customer recognition [5] - Despite challenges in the infrastructure investment landscape, the company continues to focus on its core business areas, including energy-saving and green building materials [6] Group 4: Future Growth and Strategic Planning - The company plans to enhance the proportion of high value-added products and expand its product matrix to meet diverse customer needs by 2025 [6] - Key initiatives include accelerating core business optimization, focusing on R&D innovation, and promoting intelligent manufacturing [6] Group 5: Industry Outlook and ESG Commitment - The company is positioned to benefit from trends in urban infrastructure development and green building initiatives, driven by the "dual carbon" strategy [4] - The company emphasizes green and low-carbon development, actively fulfilling its social responsibilities while pursuing sustainable growth [4]

Group 1: Impact of Trade and Market Strategy - The company has a small sales volume in the U.S. market, and the U.S.-China trade war has some impact on its business expansion in the U.S. However, the company plans to mitigate this by strengthening business development in other regions [1] - To ensure supply chain security, the company will enhance strategic inventory and promote domestic alternatives for components sourced from the U.S. [1] Group 2: Product Development and Market Focus - In the data center sector, the company is focusing on green energy solutions and actively developing liquid cooling technology, with related products in the trial phase with small-scale customers [2] - The company is advancing its product innovation in wind power and energy storage by leveraging its technological expertise and exploring industry application opportunities [1] Group 3: Industrial Park Development - The Suzhou industrial park's third phase is under construction, with production expected to commence in the first half of 2026 [3] - The first phase of the Zhongshan industrial park is planned to start production in Q4 2025, while the second phase is still under construction, with a target completion in the second half of 2026 [3] Group 4: Robotics and Automation Applications - The DA series servo products are applied in robotics, with the DA200 series used for precise motion control in smart logistics and automotive battery swap stations, while the DA180 series enhances programming efficiency for SCARA robots [4] Group 5: Profitability in Emerging Markets - In the electric vehicle sector, the company is focusing on commercial vehicles, aiming to deepen strategic partnerships and develop forward-looking products based on customer needs and industry trends [5] - For photovoltaic energy storage, the company plans to enhance product quality and performance through differentiated operations in specific niche markets [5] Group 6: Research and Development Investment - The company emphasizes R&D, with over 30 technical development achievements expected in 2024, focusing on industrial automation and AI technologies [6] - Future innovation will target performance upgrades for automation products, AI applications in predictive maintenance, and technology development in electric power products for the EV and energy storage sectors [6] Group 7: Financial Performance Insights - The company experienced a slight increase in gross margin year-on-year in Q1, but net profit margin declined due to factors including operating income and cost expenses [6] - The management aims to improve internal operational efficiency and overall profitability to enhance returns for investors [6] Group 8: Share Buyback Plans - The company remains confident in its future development and plans to complete the remaining share buyback based on stock price performance and overall market conditions [7]

A8：您好，智能手机领域，公司光学镜头业务进展顺利，高端镜头 加速渗透，产品结构持续完善。团队历经多年技术沉淀，突破高端 镜头技术壁垒。目前 7P 光学镜头、潜望长焦镜头、双群内对焦镜 头、可变光圈镜头等高端产品均已成功量产，并进入国内主流手机 厂商旗舰项目供应链。公司保持技术创新，8P 高像素主摄、三群 连续变焦、玻塑混合等前沿镜头项目已研发成功。感谢您对公司的 关注！ 2025 年 4 月 18 日投资者关系活动记录表 编号：20250418 | | □媒体采访 业绩说明会 | | | | | --- | --- | --- | --- | --- | | 投资者关系活 | | | | | | | □新闻发布会 □路演活动 | | | | | 动类别 | □现场参观 | | | | | | □其他 | | | | | 活动参与人员 | 欧菲光 2024 年度业绩网上说明会采用网络远程方式进行，面向全 | | | | | | 体投资者 | | | | | 时间 | 2025 年 4 月 18 日 15:00-17:00 | | | | | 地点 | 价值在线（https://www.ir-online.c ...

编号：2025-001 | | ☑特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | ☑其他（电话会议） | | | 会议参会人员： | | | 安联基金、安信基金、博时基金、财通证券、财通证券资管、淳厚基 | | | 金、东吴基金、东亚前海、方正证券、高盛中国、广发证券、广发资 | | | 管、国海证券、国联证券、国盛证券、国寿安保、国泰海通、弘毅远 | | | 方基金、华创证券、华金证券、华西证券、汇百川基金、汇泉基金、 | | | 金鹰基金、泾溪投资、巨杉投资、开源证券、摩根士丹利、南土资产、 | | | 复胜资产、上海国际信托、上海人寿保险、华杉投资、拾贝投资、同 | | | 泰基金、西部利得基金、信诚基金、兴业证券、长江证券、招商证券、 | | 参与单位名称及人员 | 浙商证券、中国人寿、中信建投、中信证券、朱雀基金、LCRICH | | 姓名 | CAPITAL MANAGEMENT、Pleiad Investment Advisors Limited、百嘉 | ...

证券代码：002536 证券简称：飞龙股份 飞龙汽车部件股份有限公司投资者关系活动记录表 编号：2025-013 投资者关系活动 类别 ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 ☑其他（电话会议） 参与单位名称及 人员姓名 东吴证券 郭雨蒙 长江证券 张永乾 东方资管 周扬 韩非 建信养老 王国信 纪石 时间 2025 年 4 月 18 日 地点 飞龙汽车部件股份有限公司董秘室（线上） 上市公司接待人 员姓名 副总经理、董事会秘书：谢国楼 子公司芜湖飞龙汽车电子技术研究院有限公司总经理：向晓东 投资者关系活动 主要内容介绍 一、副总经理、董事会秘书谢国楼介绍公司情况 飞龙汽车部件股份有限公司（以下简称"公司"）始建于 1952 年，至今已有 70 多年的发展历史，是一家致力于热管理系 统方案解决的上市公司。 公司发展主要分为两个阶段，第一个阶段是 2017 年之前， 公司着力汽车热管理部件产品的研发、生产和销售，比如机械 水泵、排气歧管、涡轮增压器壳体（以下简称"涡壳"）、电 子泵系列产品、温控阀系列产品和热管理温控模块等，目前汽 车水泵和涡壳两类产品已荣获 ...

Group 1: Participants Overview - The report lists a total of 148 participants from various investment and asset management firms [1][2][3][4] - Participants include representatives from well-known firms such as Goldman Sachs, Manulife, and Temasek Holdings [1][2][3][4] Group 2: Company Representation - The participants represent a diverse range of companies, including domestic and international firms [1][2][3][4] - Notable companies include Huatai Asset Management, China Life Asset Management, and CICC [1][2][3][4] Group 3: Investment Focus - The report indicates a strong interest in pharmaceutical and healthcare investments, as evidenced by the presence of multiple healthcare-focused firms [1][2][3][4] - Several participants are from firms specializing in medical and pharmaceutical investments, highlighting the sector's significance [1][2][3][4] Group 4: Event Context - The event serves as a platform for investor communication and networking among key industry players [1][2][3][4] - The diverse representation suggests a broad interest in collaboration and investment opportunities within the sector [1][2][3][4]

Group 1: Financial Performance - The company achieved a revenue of 289,195.01 million yuan in 2024, representing a year-on-year growth of 17.74% [2] - The net profit attributable to shareholders was 40,256.93 million yuan, a year-on-year increase of 15.67% [2] - The net profit excluding non-recurring items reached 40,983.41 million yuan, showing a significant growth of 55.92% [2] - Accounts receivable balance decreased by 65.62% year-on-year, with accounts receivable turnover days reduced by 29 days [2] - The net cash flow from operating activities was 91,117.22 million yuan [2] Group 2: Product Development and Market Position - Five new drugs have been launched, including innovative treatments for lung cancer and kidney cancer [3][4] - The drug Beimenna received FDA approval in December 2024 and was recommended by the NCCN guidelines, marking it as the first Chinese original innovative drug in this category [4] - The company is actively promoting the commercialization of Beidan, leveraging its clinical research and market promotion teams [4] - The drug Fumina has shown promising clinical potential in ophthalmology, with ongoing II phase clinical studies [5] Group 3: Research and Development - R&D investment for 2024 was 71,717.78 million yuan, accounting for 24.80% of total revenue [6] - The company is focusing on key R&D projects, with several innovative drug applications under review by the NMPA [6] - Collaboration with clinical oncology experts is ongoing to support investigator-initiated clinical research projects [6] Group 4: Strategic Partnerships - The company has established strategic collaborations with various organizations to enhance its R&D pipeline [7][8] - A partnership with EyePoint for the development of an ophthalmic drug has shown positive results in clinical trials [8] - The company is pursuing a dual strategy of project introduction and self-innovation to expand its treatment options [8] Group 5: Innovation Ecosystem - The company is building an innovation ecosystem to promote collaboration and resource sharing among various stakeholders [9] - A partnership with He Yuan Bio for the commercialization of a plant-derived human serum albumin injection has been established [9] - Investment in Repu Morning Creation for stem cell therapy development is underway, with clinical trials for core products already initiated [10]

证券代码：300039 证券简称：上海凯宝 上海凯宝药业股份有限公司 5、陈总监好！看了2024分季度财务指标，营收是4.753.532.923.52。 利润是 0.880.530.741.58。第四季度利润是 1.58 亿，利润怎么翻 了倍？请赐教？ 投资者关系活动记录表 编号：2025-001 投资者关系 活动类别 □特定对象调研 □分析师会议 □媒体采访 ☑业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） | 参与单位名称及 | 参与公司 2024 年度业绩说明会的广大投资者 | | --- | --- | | 人员姓名 | | | 时 间 | 2025 年 4 月 18 日 下午 15:00-17：00 | | 地 点 | 全景网"投资者关系互动平台"（http://rs.p5w.net） 1.董事长穆竟伟女士 | | | 2.总经理周迎宾先生 | | 上市公司接待人 | | | | 3.独立董事马洪先生 | | 员姓名 | 4.财务总监陈友龙先生 | | | 5.董事会秘书任立旺先生 | | | 一、本次活动介绍 | | | 公司于 2025 年 4 月 18 日 ...

证券代码：002183 证券简称：怡亚通 深圳市怡亚通供应链股份有限公司 投资者关系活动记录表 编号：2025-003 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 线上参与公司2024年度业绩网上说明会的投资者 | | 时间 | 2025年04月18日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | 上市公司接待人员姓名 | 董事长兼总经理 周国辉 | | | 副总经理兼财务总监 莫京 | | | 副总经理兼董事会秘书 吕品 | | | 独立董事 邓建新 （一）请问年会中提出的千亿市值万亿生态口号将如何完成？ | | 投资者关系活动主要内容 | 子公司何时上市？ 答:尊敬的投资者，您好！2025年是"十四五"规划收官之年、 | | | "十五五"规划谋篇布局之年，也是进一步全面深化改革、推动中国 | | 介绍 | 式 ...